About
Precision BioSciences develops and licenses genome-editing technologies centered on its ARCUS nuclease platform to enable targeted in vivo and ex vivo DNA modifications for therapeutic cell therapies, gene editing treatments, and other biotechnology applications.
Explore Precision BioSciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.